- $143.50bn
- $192.37bn
- $63.63bn
- 98
- 86
- 87
- 100
Pfizer Inc - Regulatory Approval
AnnouncementPfizer Inc - Pfizer Reports Third-Quarter 2008 Results
AnnouncementPfizer Inc - Pfizer Declares a 32-Cent Third Quarter 2008 Dividend
AnnouncementPfizer Inc - New Data Show Pfizers Axitinib Prolonged Overall Survival in Advan
AnnouncementPfizer Inc - Bextra Status
AnnouncementPfizer Inc - Pfizer Reports Shares of Encysive Pharmaceuticals Inc. Tendered Pur
AnnouncementPfizer Inc - Overweight Dogs in Europe to Benefit from Pfizer U.S. Experience
AnnouncementPfizer Inc Re Contract
AnnouncementPfizer Inc - Regulatory Approval
AnnouncementPfizer Inc - Pfizers Celsentri(R) Approved in the European Union, Providing a N
AnnouncementPfizer Inc - Patients Who Took Investigational Melanoma Compound CP-675,206 Show
AnnouncementPfizer Inc - Single-Agent SUTENT Prolonged Progression-Free Survival across All
AnnouncementPfizer Inc - New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients wit
AnnouncementPfizer Inc Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post
AnnouncementPfizer Inc - Patients Treated with Lipitor Were Significantly Less Likely to Hav
AnnouncementPfizer Inc - Court Rules for Pfizer in Patent Infringement Case on Neurontin
AnnouncementPfizer Inc - Pfizer Receives Initial Communication from U.S. Patent and Trademar
AnnouncementPfizer Inc - Research Update
AnnouncementRule 2.10 Announcement
Announcement